Plasma NfL was measured with ultrasensitive digital immunoassay-based technology at baseline and 1-year follow-up in a pilot cohort of 15 PSP patients and 12 healthy controls, and a validation cohort of 147 PSP patients. 
ultrasensitive digital immunoassay-based technology
Mixed linear models tested the ability of plasma NfL to predict neurological, cognitive and functional decline, and brain atrophy.



mixed linear models